JP2023182632A5 - - Google Patents

Info

Publication number
JP2023182632A5
JP2023182632A5 JP2023155476A JP2023155476A JP2023182632A5 JP 2023182632 A5 JP2023182632 A5 JP 2023182632A5 JP 2023155476 A JP2023155476 A JP 2023155476A JP 2023155476 A JP2023155476 A JP 2023155476A JP 2023182632 A5 JP2023182632 A5 JP 2023182632A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
moderate
once
skin
nemolizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023155476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023182632A (ja
Filing date
Publication date
Priority claimed from JP2020542801A external-priority patent/JP7777921B2/ja
Application filed filed Critical
Publication of JP2023182632A publication Critical patent/JP2023182632A/ja
Publication of JP2023182632A5 publication Critical patent/JP2023182632A5/ja
Pending legal-status Critical Current

Links

JP2023155476A 2018-02-09 2023-09-21 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ Pending JP2023182632A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
US62/628,714 2018-02-09
JP2020542801A JP7777921B2 (ja) 2018-02-09 2019-02-08 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020542801A Division JP7777921B2 (ja) 2018-02-09 2019-02-08 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ

Publications (2)

Publication Number Publication Date
JP2023182632A JP2023182632A (ja) 2023-12-26
JP2023182632A5 true JP2023182632A5 (cg-RX-API-DMAC7.html) 2025-11-13

Family

ID=65729402

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020542801A Active JP7777921B2 (ja) 2018-02-09 2019-02-08 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
JP2023155476A Pending JP2023182632A (ja) 2018-02-09 2023-09-21 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
JP2025151311A Pending JP2025176134A (ja) 2018-02-09 2025-09-11 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020542801A Active JP7777921B2 (ja) 2018-02-09 2019-02-08 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025151311A Pending JP2025176134A (ja) 2018-02-09 2025-09-11 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ

Country Status (23)

Country Link
US (2) US12435147B2 (cg-RX-API-DMAC7.html)
EP (2) EP4644424A3 (cg-RX-API-DMAC7.html)
JP (3) JP7777921B2 (cg-RX-API-DMAC7.html)
CN (1) CN112040976A (cg-RX-API-DMAC7.html)
AU (2) AU2019219608B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016144A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090062A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002050A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749353T3 (cg-RX-API-DMAC7.html)
ES (1) ES3049513T3 (cg-RX-API-DMAC7.html)
FI (1) FI3749353T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251101T1 (cg-RX-API-DMAC7.html)
IL (1) IL276524A (cg-RX-API-DMAC7.html)
LT (1) LT3749353T (cg-RX-API-DMAC7.html)
MX (1) MX2020008193A (cg-RX-API-DMAC7.html)
PH (1) PH12020551185A1 (cg-RX-API-DMAC7.html)
PL (1) PL3749353T3 (cg-RX-API-DMAC7.html)
PT (1) PT3749353T (cg-RX-API-DMAC7.html)
RU (1) RU2758378C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007558YA (cg-RX-API-DMAC7.html)
SI (1) SI3749353T1 (cg-RX-API-DMAC7.html)
TW (2) TWI856006B (cg-RX-API-DMAC7.html)
WO (1) WO2019155427A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535464A (zh) * 2023-11-02 2025-09-16 日商丸寶股份有限公司 醫藥組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
FI3284480T3 (fi) * 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2017093857A1 (en) * 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions

Similar Documents

Publication Publication Date Title
US20230058134A1 (en) Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
Kamisako et al. Interstitial pneumonitis and interferon-alfa
Lane A steroid sparing effect of ketotifen in steroid‐dependent asthmatics
TWI863995B (zh) 皮膚型紅斑狼瘡之治療
US11458113B2 (en) Topical formulations and treatments
Walker et al. Benylin (dextromethorphan) abuse and mania
Gong et al. Feitai attenuates bleomycin-induced pulmonary fibrosis in rats
CN117159553A (zh) 慢性手部湿疹的治疗
Comas et al. Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion
JP2021512917A5 (cg-RX-API-DMAC7.html)
JP2002530327A (ja) 硝酸ミコナゾールによる陰門膣カンジダ症を治療するための方法および装置
Kosmidis et al. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection
Jenkins et al. A controlled study of slow-release theophylline and aminophylline in patients with chronic bronchitis
Cade et al. Prophylactic paracetamol for analgesia after vaginal termination of pregnancy
JP2023534576A5 (cg-RX-API-DMAC7.html)
RU2637413C1 (ru) Способ лечения хронического воспаления слизистой оболочки рта с элементами гиперкератоза у лиц молодого возраста
JP2007517853A (ja) 心臓保護のための強心剤と組み合わせたジクロロアセテート
AU5668596A (en) Irritation relief using nonsteroidal anti-inflammatory compounds
Khaneshan et al. Proven Cutaneous Mucormycosis in a COVID-19 Patient: A Case Report and Literature Review
US4751236A (en) Method for treating genital herpes
Shimada et al. Cutaneous Nocardiosis in the Very Elderly: A Case of Lymphocutaneous Infection and a Literature Review of Patients Aged Over 85 Years
CN118766927A (zh) 更昔洛韦的新用途
Hirohata et al. Quantitative analysis of hemoglobin content of regenerating epithelium in gastric ulcer patients
CN115990210A (zh) 用于治疗斑秃的外用中药:复方藤黄斑秃生发酊